WOCKPHARMA2019-01-012019-03-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2019-01-012019-03-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2019-01-012019-03-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2019-01-012019-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2018-04-01 2019-03-31 2019-04-19 INR Crores Yearly Single segment Pharmaceuticals 2019-01-01 2019-03-31 Audited Standalone 4674000000.00 83900000.00 4757900000.00 993200000.00 776500000.00 42600000.00 791400000.00 473600000.00 354500000.00 2153400000.00 5585200000.00 -827300000.00 0.00 -827300000.00 0.00 -492100000.00 -492100000.00 0.00 -335200000.00 0.00 0.00 0.00 0.00 -335200000.00 -13700000.00 -348900000.00 0.00 0.00 553400000.00 5 -3.03 -3.03 0.00 0.00 -3.03 -3.03 Notes to Standalone Results n1 The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 06, 2019. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the quarter year ended March 31, 2019. n2 During the year, the Company has allotted 55750 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. n3 During the year, the Company has allotted 500,000,000 4 percentage Non Convertible Non Cumulative Redeemable Preference Shares NCCRPS of Face Value of Rs. 5 each, at par, on preferential basis to the Promoter Group, for an aggregate amount of Rs. 250 crore in accordance with the approval of the Shareholders of the Company obtained on December 14, 2018. n4 During the year, the Company has redeemed out of the proceeds of fresh issue of NCCRPS referred at Note 3 above, i 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares OCCRPS Series 2 of Face value of Rs. 5 each; and ii 315,659,941 Non Convertible Cumulative Redeemable Preference Shares NCRPS Series 2 and Series 3 of Face value of Rs. 5 each, as per terms and conditions of the said Preference Shares, on its due date of redemption i.e. December 31, 2018. The redemption amount was Rs. 271.34 crore including redemption premium of Rs. 52.78 crore. n5 During the year, the Company has extended the redemption period of 160,000,000, 0.01percentage Non-Convertible Cumulative Redeemable Preference Shares (NCRPS Series 5) held by the Promoter Group which were due for redemption on March 31, 2019 by a year i.e. upto March 31, 2020 with a right to earlier redemption, by giving one month notice by either parties post June 30, 2019. Premium at 4 percentage p.a. shall be payable for the extended period upto the date of redemption. n6 Effective April 01, 2018, the Company has adopted Ind AS 115 Revenue from Contracts with Customers that has become mandatorily applicable for reporting periods beginning on or after April 01, 2018 replacing the existing revenue recognition standard. In accordance with the first time adoption options available in the said standard, the Company has chosen the cumulative effect method and applied retrospectively only to contracts that are not completed as at the date of initial application i.e. April 01, 2018. Accordingly, the comparatives have not been restated in line with the provisions of the standard. The adoption of the standard did not have any material impact to the financial statements of the Company for the quarter and year ended March 31, 2019. n7 The Company has paid dividend of 0.01percentage at the rate of Rs. 0.0005 per share of Rs. 5 each) amounting to Rs. 218,556 on the preference shares redeemed during the year. Further subject to the approval of the Shareholders in the Annual General meeting, the Board also recommends dividend of n0.01percentage at the rate of Rs. 0.0005 per share of Rs. 5 each on the balance 160,000,000 Non Convertible Cumulative Redeemable Preference shares NCRPS Series 5 of Rs. 5 each amounting to Rs. 80,000. n4percentage at the rate of Rs. 0.055 per share of Rs. 5 each on the 500,000,000 Non Convertible Non Cumulative Redeemable Preference shares NCCRPS of Rs. 5 each amounting to Rs. 27,397,260 for the period commencing from date of allotment till March 31, 2019. n8 Figures for the quarter ended March 31, 2019 and March 31, 2018 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of the relevant financial year. n9 The Company is exclusively into Pharmaceutical business Segment n10 Previous period year figures have been recast or re grouped to conform to the current periods years presentation. n11 Additional Note Earning per share for the quarter ended 31st March 2019 is not annualised. 2018-04-01 2019-03-31 Audited Standalone 21499500000.00 310000000.00 21809500000.00 4647300000.00 4024800000.00 50300000.00 4822000000.00 1706300000.00 1219100000.00 7094000000.00 23563800000.00 -1754300000.00 0.00 -1754300000.00 0.00 -935400000.00 -935400000.00 0.00 -818900000.00 0.00 0.00 0.00 0.00 -818900000.00 -12000000.00 -830900000.00 0.00 0.00 553400000.00 5 11712900000.00 -7.40 -7.40 0.00 0.00 -7.40 -7.40 Exchange Fluctuation (loss) / gain, net 94800000.00 Other Expenses 2058600000.00 Exchange Fluctuation (loss) / gain, net -38000000.00 Other Expenses 7132000000.00 0.00 0.00 0.00